Montelukast Bluefish Pharma (Montelukast)

Montelukast selectively blocks the cysteinyl leukotriene receptor CysLT1, preventing leukotriene D4 from binding. By inhibiting this pathway, it reduces bronchoconstriction, mucus production, vascular leakage, and inflammatory cell recruitment, leading to improved airway patency and decreased allergic inflammation.

The appropriate dose of Montelukast Bluefish Pharma is determined by the prescribing healthcare professional based on the patient’s age, condition, and clinical response. Dosage instructions are individualized and should be followed exactly as written on the prescription label.

Safety data for Montelukast during pregnancy and lactation are limited. The medication should only be used if the potential benefit justifies any possible risk to the fetus or infant, and decisions should be made in consultation with a qualified healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Montelukast belongs to the leukotriene receptor antagonist class, offering an oral alternative to inhaled corticosteroids or long‑acting beta‑agonists. It is particularly useful for patients with aspirin‑sensitive asthma or those who need additional control of allergic symptoms, though it may be less potent for acute bronchospasm relief.

Montelukast Bluefish Pharma should be stored below 25 °C in its original packaging, protected from moisture and direct light. Keeping the product in a dry, temperature‑controlled environment helps maintain its stability and potency throughout its shelf life.

The medication is taken orally, usually as a tablet, with or without food as directed by the prescriber. Consistency in the time of day helps maintain steady drug levels, and patients should swallow the tablet whole with water unless otherwise instructed.

Serious adverse events, though rare, include angioedema, severe skin reactions such as Stevens‑Johnson syndrome, and neuropsychiatric effects like depression, anxiety, or suicidal thoughts. Any sudden swelling, rash, or mood changes should prompt immediate medical evaluation.

Montelukast is contraindicated in individuals with known hypersensitivity to the drug or any of its excipients. Patients with a history of severe allergic reactions to leukotriene modifiers should avoid its use, and clinicians should assess suitability on a case‑by‑case basis.